ClinicalTrials.gg
TerminatedNCT04931667Updated Mar 31, 2026Results posted

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

A Phase 3 interventional study of Lorecivivint in Osteoarthritis of the Knee, sponsored by Biosplice Therapeutics, Inc.. Terminated at 4 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Biosplice Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Study was terminated by Sponsor based on a business decision not due to safety. The study report was finalized without any statistical analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
344th of 691
72 · median 72
Started
2021
with 59 others
Phase 3
76 of 796
6 open now
Registered
590th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 344th largest by enrollment of the 691 interventional ones that give a count, is one of 60 that started in 2021, is one of 76 in phase 3, and was the 590th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.

Read the detailed description

At Day 1, after a screening period of up to 14 days, subjects will receive an IA injection of 0.07 mg LOR into one or both knees, followed by a 36-month evaluation period.

Clinic visits will be scheduled at Day 1, and Months 3, 12, 24, and 36 [End of study (EOS)] or Early Termination (ET).

All Patient Reported Outcome (PRO) measurements, including Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and Pain Numeric Rating Scale (NRS), as well as safety evaluations will be conducted at each clinic visit. An additional phone follow-up visit for safety will occur 4 weeks after the injection on Day 1.

Study was terminated by Sponsor based on a business decision not due to safety. The study report was finalized without any statistical analysis.

03

Conditions studied

  • Osteoarthritis of the Knee

Keywords

  • SM04690
  • Wnt pathway inhibitor
  • osteoarthritis
  • Biosplice Therapeutics, Inc.
  • Lorecivivint
  • DYRK inhibitor
  • CLK inhibitor
  • Samumed
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females between 40 and 80 years of age, inclusive, in general good health apart from their knee OA
  2. Femorotibial OA by standard American College of Rheumatology (ACR) criteria; knee OA is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis).
  3. Pain compatible with knee OA for at least 26 weeks prior to the Screening Visit
  4. Negative drug test for amphetamine, buprenorphine, cocaine, methadone, opiates, phencyclidine (PCP), propoxyphene, barbiturates, and benzodiazepine, unless any of these drugs are prescribed by a physician to treat a specific condition
  5. Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
  6. Subjects must have read and understood the form (ICF), and must have signed and dated it prior to any study-related procedure being performed

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women, breastfeeding women, and women who are not (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) who have a positive or indeterminate pregnancy test result at Screening and Day 1
  2. Women who are not post-menopausal or permanently surgically sterile who are sexually active, and who are not willing to use during the study period
  3. Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to Day 1
  4. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, -rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA within 12 weeks prior to Day 1
  5. Any condition that, in the opinion of the Investigator, constitutes a risk or for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  6. Any comorbid condition that could affect study endpoint assessments of the knee, including, but not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gout or pseudogout, and fibromyalgia
  7. Any contraindications for an IA injection in the knee(s) to be injected at Day 1 in the opinion of the Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    0.07 mg Lorecivivint

    One intra-articular injection of 0.07 mg Lorecivivint in 2 ml vehicle in one or both knees as clinically indicated. Bilateral injection of 0.07 mg LOR are allowed. Lorecivivint: Healthcare professional-administered intra-articular injection

    Drug: Lorecivivint

Interventions

  • Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.

    Also known as: SM04690

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Left Knee

    Change from baseline in pain numeric rating scale (NRS) score for the left knee. The pain NRS is an 11-point scale \[0-10\] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

    Time frame: Three Months after Day 1 Injection

  2. Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Right Knee

    Change from baseline in pain numeric rating scale (NRS) score for the right knee. The pain NRS is an 11-point scale \[0-10\] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

    Time frame: Three Months after Day 1 Injection

Secondary outcomes

  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Left Knee

    Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 physical function subscore (WOMAC Function) in left knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore ranges from 0 to 170 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

    Time frame: Three Months after Day 1 Injection

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Right Knee

    Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 physical function subscore (WOMAC Function) in right knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore ranges from 0 to 170 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

    Time frame: Three Months after Day 1 Injection

  3. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Left Knee

    Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 pain subscore (WOMAC Pain) in left knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore ranges from 0 to 50 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

    Time frame: Three Months after Day 1 Injection

  4. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Right Knee

    Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 pain subscore (WOMAC Pain) in right knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore ranges from 0 to 50 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

    Time frame: Three Months after Day 1 Injection

07

Results

Posted Mar 31, 2026

Participant flow

Participant flow — Overall Study
Milestone0.07 mg Lorecivivint
Started72
Completed0
Not completed72
Withdrew: Lost to follow-up2
Withdrew: Study terminated by sponsor63
Withdrew: Withdrawal by subject7

Outcome measures

PrimaryChange From Baseline in Pain Numeric Rating Scale (NRS) Score for the Left Knee

Change from baseline in pain numeric rating scale (NRS) score for the left knee. The pain NRS is an 11-point scale \[0-10\] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

Time frame:
Three Months after Day 1 Injection
Reported as:
Mean · units on a scale
Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Left Knee
units on a scale0.07 mg Lorecivivint
Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Left Knee-0.9 (-6 to 4)
PrimaryChange From Baseline in Pain Numeric Rating Scale (NRS) Score for the Right Knee

Change from baseline in pain numeric rating scale (NRS) score for the right knee. The pain NRS is an 11-point scale \[0-10\] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

Time frame:
Three Months after Day 1 Injection
Reported as:
Mean · units on a scale
Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Right Knee
units on a scale0.07 mg Lorecivivint
Change From Baseline in Pain Numeric Rating Scale (NRS) Score for the Right Knee-1.2 (-5 to 3)
SecondaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Left Knee

Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 physical function subscore (WOMAC Function) in left knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore ranges from 0 to 170 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

Time frame:
Three Months after Day 1 Injection
Reported as:
Mean · units on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Left Knee
units on a scale0.07 mg Lorecivivint
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Left Knee-13.4 (-58.2 to 20)
SecondaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Right Knee

Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 physical function subscore (WOMAC Function) in right knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore ranges from 0 to 170 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

Time frame:
Three Months after Day 1 Injection
Reported as:
Mean · units on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Right Knee
units on a scale0.07 mg Lorecivivint
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscore (WOMAC Function) in Right Knee-13.5 (-46.9 to 5.9)
SecondaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Left Knee

Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 pain subscore (WOMAC Pain) in left knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore ranges from 0 to 50 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

Time frame:
Three Months after Day 1 Injection
Reported as:
Mean · units on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Left Knee
units on a scale0.07 mg Lorecivivint
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Left Knee-16.8 (-56 to -16)
SecondaryChange From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Right Knee

Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index NRS3.1 pain subscore (WOMAC Pain) in right knee. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain, stiffness, and physical functioning of a target joint. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore ranges from 0 to 50 (raw) and will be scaled 0 to 100 for reporting. Change was calculated as three-month visit minus baseline; a negative value indicates improvement while a positive value indicates worsening.

Time frame:
Three Months after Day 1 Injection
Reported as:
Mean · units on a scale
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Right Knee
units on a scale0.07 mg Lorecivivint
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscore (WOMAC Pain) in Right Knee-13.7 (-36 to 8)

Adverse events

Collected over Adverse events were assessed at each in-person and phone visit from the time of study injection(s) on Day 1 through the end of the study (Day 116 / four months duration).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.07 mg Lorecivivint0/72 (0%)0/72 (0%)2/72 (2.8%)
Most frequent other events
Most frequent other events
Event0.07 mg Lorecivivint
ArthralgiaMusculoskeletal and connective tissue disorders1/72
Bacterial VaginosisInfections and infestations1/72

Baseline characteristics

All subjects who received a study injection without previous exposure to Lorecivivint.

Age, Continuous
Age, Continuous(years)0.07 mg Lorecivivint
Mean61.5 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)0.07 mg Lorecivivint
Female42
Male30
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.07 mg Lorecivivint
Hispanic or Latino12
Not Hispanic or Latino60
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.07 mg Lorecivivint
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American11
White58
More than one race0
Unknown or Not Reported0
Symptomatic OA Laterality by Investigator Assessment
Symptomatic OA Laterality by Investigator Assessment(Participants)0.07 mg Lorecivivint
Bilateral58
Unilateral, Right10
Unilateral, Left4
08

Study locations

4 sites
  • Research Site
    Tucson, Arizona 85712, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Oak Brook, Illinois 60523, United States
  • Research Site
    Dallas, Texas 75231, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Dec 2021, 4 months.

Results were first posted in Mar 2026, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Jun 18, 2021
StartActual
Jul 15, 2021
Primary completionActual
Dec 13, 2021
CompletionActual
Dec 13, 2021
Results first posted
Mar 31, 2026
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04931667
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Jul 15, 2021
Primary completion
Dec 13, 2021
Completion
Dec 13, 2021
Results posted
Mar 31, 2026
Last update
Mar 31, 2026

Study contacts

Yusuf Yazici, MD
study director · Biosplice Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorecivivint

Start the discussion